304 related articles for article (PubMed ID: 30841025)
1. LncRNA MALAT1 Depressed Chemo-Sensitivity of NSCLC Cells through Directly Functioning on miR-197-3p/p120 Catenin Axis.
Yang T; Li H; Chen T; Ren H; Shi P; Chen M
Mol Cells; 2019 Mar; 42(3):270-283. PubMed ID: 30841025
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-142-3p/MALAT1 inhibits lung cancer progression through repressing β-catenin expression.
Liu J; Tian W; Zhang W; Jia Y; Yang X; Wang Y; Zhang J
Biomed Pharmacother; 2019 Jun; 114():108847. PubMed ID: 30970294
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
4. NORAD accelerates chemo-resistance of non-small-cell lung cancer via targeting at miR-129-1-3p/SOX4 axis.
Huang Q; Xing S; Peng A; Yu Z
Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31894841
[TBL] [Abstract][Full Text] [Related]
5. m
Jin D; Guo J; Wu Y; Du J; Yang L; Wang X; Di W; Hu B; An J; Kong L; Pan L; Su G
J Hematol Oncol; 2019 Dec; 12(1):135. PubMed ID: 31818312
[TBL] [Abstract][Full Text] [Related]
6. Targeting MALAT1 induces DNA damage and sensitize non-small cell lung cancer cells to cisplatin by repressing BRCA1.
Huang J; Lin C; Dong H; Piao Z; Jin C; Han H; Jin D
Cancer Chemother Pharmacol; 2020 Nov; 86(5):663-672. PubMed ID: 33030583
[TBL] [Abstract][Full Text] [Related]
7. MiR-221-3p-mediated downregulation of MDM2 reverses the paclitaxel resistance of non-small cell lung cancer in vitro and in vivo.
Ni L; Xu J; Zhao F; Dai X; Tao J; Pan J; Shi A; Shen Z; Su C; Zhang Y
Eur J Pharmacol; 2021 May; 899():174054. PubMed ID: 33771522
[TBL] [Abstract][Full Text] [Related]
8. LncRNA MALAT1 promotes migration and invasion of non-small-cell lung cancer by targeting miR-206 and activating Akt/mTOR signaling.
Tang Y; Xiao G; Chen Y; Deng Y
Anticancer Drugs; 2018 Sep; 29(8):725-735. PubMed ID: 29916897
[TBL] [Abstract][Full Text] [Related]
9. Long Noncoding RNA SNHG6 Promotes Proliferation and Inhibits Apoptosis in Non-small Cell Lung Cancer Cells by Regulating miR-490-3p/RSF1 Axis.
Dong Z; Liu H; Zhao G
Cancer Biother Radiopharm; 2020 Jun; 35(5):351-361. PubMed ID: 32202941
[No Abstract] [Full Text] [Related]
10. LncRNA MALAT1 accelerates non-small cell lung cancer progression via regulating miR-185-5p/MDM4 axis.
Wang D; Zhang S; Zhao M; Chen F
Cancer Med; 2020 Dec; 9(23):9138-9149. PubMed ID: 33146951
[TBL] [Abstract][Full Text] [Related]
11. Solamargine enhanced gefitinib antitumor effect via regulating MALAT1/miR-141-3p/Sp1/IGFBP1 signaling pathway in non-small cell lung cancer.
Tang Q; Zhou Q; Li J; Yang X; Wang R; Wang X; Xu M; Han L; Wu W; Wang S
Carcinogenesis; 2023 Aug; 44(6):497-510. PubMed ID: 37144780
[TBL] [Abstract][Full Text] [Related]
12. Depletion of lncRNA MALAT1 inhibited sunitinib resistance through regulating miR-362-3p-mediated G3BP1 in renal cell carcinoma.
Wang Z; Chang X; Zhu G; Gao X; Chang L
Cell Cycle; 2020 Aug; 19(16):2054-2062. PubMed ID: 32663095
[TBL] [Abstract][Full Text] [Related]
13. LncRNA H19 interacted with miR-130a-3p and miR-17-5p to modify radio-resistance and chemo-sensitivity of cardiac carcinoma cells.
Jia J; Zhang X; Zhan D; Li J; Li Z; Li H; Qian J
Cancer Med; 2019 Apr; 8(4):1604-1618. PubMed ID: 30843379
[TBL] [Abstract][Full Text] [Related]
14. LncRNA MALAT1 contributes to non-small cell lung cancer progression via modulating miR-200a-3p/programmed death-ligand 1 axis.
Wei S; Wang K; Huang X; Zhao Z; Zhao Z
Int J Immunopathol Pharmacol; 2019; 33():2058738419859699. PubMed ID: 31240979
[TBL] [Abstract][Full Text] [Related]
15. Upregulated lncRNA SNHG1 contributes to progression of non-small cell lung cancer through inhibition of miR-101-3p and activation of Wnt/β-catenin signaling pathway.
Cui Y; Zhang F; Zhu C; Geng L; Tian T; Liu H
Oncotarget; 2017 Mar; 8(11):17785-17794. PubMed ID: 28147312
[TBL] [Abstract][Full Text] [Related]
16. circ_0007385 served as competing endogenous RNA for miR-519d-3p to suppress malignant behaviors and cisplatin resistance of non-small cell lung cancer cells.
Ye Y; Zhao L; Li Q; Xi C; Li Y; Li Z
Thorac Cancer; 2020 Aug; 11(8):2196-2208. PubMed ID: 32602212
[TBL] [Abstract][Full Text] [Related]
17. The lncRNA RHPN1-AS1 downregulation promotes gefitinib resistance by targeting miR-299-3p/TNFSF12 pathway in NSCLC.
Li X; Zhang X; Yang C; Cui S; Shen Q; Xu S
Cell Cycle; 2018; 17(14):1772-1783. PubMed ID: 30010468
[TBL] [Abstract][Full Text] [Related]
18. MiR-133a-3p attenuates resistance of non-small cell lung cancer cells to gefitinib by targeting SPAG5.
Li Q; Wang Y; He J
J Clin Lab Anal; 2021 Jul; 35(7):e23853. PubMed ID: 34057242
[TBL] [Abstract][Full Text] [Related]
19. MALAT1 enhances gemcitabine resistance in non-small cell lung cancer cells by directly affecting miR-27a-5p/PBOV1 axis.
Chen W; Tan X; Yang Q; Fang Z; Xu Y
Cell Signal; 2022 Jun; 94():110326. PubMed ID: 35367362
[TBL] [Abstract][Full Text] [Related]
20. The lncRNA MALAT1 contributes to non-small cell lung cancer development via modulating miR-124/STAT3 axis.
Li S; Mei Z; Hu HB; Zhang X
J Cell Physiol; 2018 Sep; 233(9):6679-6688. PubMed ID: 29215698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
